The recent guideline on remdesivir issued by the World Health Organization (WHO), which has advised against the use of the COVID-19 drug to treat hospitalized patients, is still subject to review, according to head of the COVID-19 Task Force at the Georgetown Public Hospital Dr. Mahendra Carpen.
In a recent interview with Stabroek News, Dr. Carpen, who also heads the Solidarity Trial on remdesivir in the country, made this revelation when he was asked if Guyana will discontinue the use of the drug to treat COVID-19 patients based on the WHO’s pronouncement.
In its “Therapeutics and COVID-19- Living Guidelines,” which was published on November 20th, the WHO recommended that the current practice of using remdesivir to treat hospitalized patients should be discontinued based on a study.
